Please assess the completion status of the following clinical trial:

Trial Title: An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed CIN 2/3 that requires surgical intervention~Exclusion Criteria:~* Previous history of listeriosis~* Steroid use~* Antibiotic use~* Negative anergy panel~* HIV positive~* Pregnant or actively trying during the treatment period~* Intercurrent disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose (Type: EXPERIMENTAL): 5x10\^7 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
- Middle Dose (Type: EXPERIMENTAL): 3.3x10\^8 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
- High Dose (Type: EXPERIMENTAL): 1x10\^9 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
- Placebo (Type: PLACEBO_COMPARATOR): normal saline x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.

Based on this trial design, predict the completion outcome and termination type (if applicable).